Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer
Completed · Phase 1
Conditions studied: Microsatellite Stable Colorectal Cancer
In brief
This study will be conducted in adult participants diagnosed with any form of an advanced or progressive MSS CRC for which 1st and 2nd line standard therapy (at least one of which contained fluorouracil) is no longer effective or is intolerable. This is a phase 1b, multi-center, open label study designed to assess safety and tolerability of grapiprant in combination with pembrolizumab, to determine the recommended phase 2 dose (RP2D) with pembrolizumab, and to evaluate and characterize the PK of grapiprant alone and in combination with pembrolizumab. Disease response, pharmacodynamics, and response biomarkers will also be assessed.
Key facts
- Study ID
- NCT03658772
- Run by
- Arrys Therapeutics
- People needed
- 54
- Starts
- 2018-09-20
- Expected to finish
- 2023-03-07
- Last updated by the study team
- 2023-10-24
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic Cancer Center - Scottsdale — Phoenix, Arizona, United States
- University of Colorado Denver-Anschutz Medical Campus — Aurora, Colorado, United States
- Sarah Cannon Research Institute, LLC (SCRI) — Nashville, Tennessee, United States
- New Experimental Therapeutics of San Antonio-NEXT Oncology — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.